{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:20:08Z","timestamp":1787016008493,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Ferumoxytol is an intravenous (IV) iron formulation for treatment of iron deficiency (ID) that faced post\u2010marketing reports of serious adverse events (SAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>To determine the safety and efficacy of ferumoxytol compared to other iron formulations and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We searched the Cochrane Library, Medline, and EMBASE from inception until February 2018 as well as trial registries and reference lists of relevant articles for randomized or quasi\u2010randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The review included nine studies with 5691 participants. Studies were at low risk of bias.<\/jats:p>\n                    <jats:p>When comparing ferumoxytol to other IV iron formulations, there is moderate quality evidence (QE) of little to no difference in treatment emergent adverse events (TEAEs) (risk ratio [RR] 0.88, 95% confidence interval [CI] 0.80\u20100.97), treatment related adverse events (TRAEs) (RR 0.73, 95% CI 0.61\u20100.88), SAEs (RR 1.13, 95% CI 0.77\u20101.67), hypotension or hypersensitivity reactions (RR 0.58, 95% CI 0.31\u20101.09), or composite cardiovascular outcomes (RR 0.56, 95% CI 0.24\u20101.29), low QE of little to no difference in related SAEs (RR 0.55, 95% CI 0.05\u20106.16), and high QE of little to no difference in the number of patients with an increase in hemoglobin by at least 1 g\/dL (RR 1.04, 95% CI 0.96\u20101.12).<\/jats:p>\n                    <jats:p>Ferumoxytol had less TEAEs compared to oral iron (RR 0.78, 95% CI 0.61\u20100.98), but more compared to placebo (RR 1.62, 95% CI 1.01\u20102.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Ferumoxytol is as efficacious and safe as alternative IV iron formulations with no clear safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.15587","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T04:09:50Z","timestamp":1574654990000},"page":"3646-3656","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The safety and efficacy of ferumoxytol in the treatment of iron deficiency: a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-2406","authenticated-orcid":false,"given":"Jameel","family":"Abdulrehman","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine University Healthy Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-8536","authenticated-orcid":false,"given":"Grace H.","family":"Tang","sequence":"additional","affiliation":[{"name":"Hematology Oncology Clinical Research Group St. Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-8647","authenticated-orcid":false,"given":"Michael","family":"Auerbach","sequence":"additional","affiliation":[{"name":"Department of Medicine Georgetown University School of Medicine  Washington DC USA"},{"name":"Auerbach Hematology and Oncology  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Santesso","sequence":"additional","affiliation":[{"name":"McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1220-0301","authenticated-orcid":false,"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine St. Michael's Hospital  Toronto Ontario Canada"},{"name":"Department of Laboratory Medicine and Pathobiology St. Michael's Hospital  Toronto Ontario Canada"},{"name":"Li Ka Shing Knowledge Institute St. Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540360041028"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1967.03120120085014"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90192-X"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01846.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665118000149"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-013-1042-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401038"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24201"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117383"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00396-X"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-2-231"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.57"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24326"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.12.1327"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15572"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23534"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02130.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000451069"},{"key":"e_1_2_8_21_1","unstructured":"Highlights of prescribing information [Internet]. United States Food & Drug Administration [cited 2019 Feb 22]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022180s009lbl.pdf."},{"key":"e_1_2_8_22_1","unstructured":"Health Canada approves feraheme (ferumoxtyol) to treat iron deficiency in adults with chronic kidney disease [Internet]. AMAG pharmaceuticals [cited 2019 June 23]. Available from:http:\/\/ir.amagpharma.com\/news-releases\/news-release-details\/health-canada-approves-ferahemer-ferumoxytol-treat-iron."},{"key":"e_1_2_8_23_1","unstructured":"Withdrawal of the application for a change to the marketing authorisation for Rienso (ferumoxytol) [Internet]. European Medicines Agency [cited 2018 August 15]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2015\/02\/WC500183309.pdf."},{"key":"e_1_2_8_24_1","unstructured":"FERAHEME (ferumoxytol) \u2010 New Restrictions on the Use due to Information on Serious Allergic Reactions \u2010 For Health Professionals [Internet]. Health Canada [cited 2019 June 23]. Available from:http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2014\/40505a-eng.php."},{"key":"e_1_2_8_25_1","unstructured":"FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol) [Internet]. United States Food & Drug Administration [cited 2019 June 23]. Available from:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-warnings-and-changes-prescribing-instructions-decrease."},{"key":"e_1_2_8_26_1","unstructured":"Drug product database online query [Internet]. Health Canada [cited 2019 Feb 22]. Available from:https:\/\/health-products.canada.ca\/dpd-bdpp\/."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.10.007"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25060"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23712"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05320513"},{"key":"e_1_2_8_31_1","unstructured":"Higgins JPT GSeCHfSRoIVuMTCC 2011. [cited on May 3 2018].https:\/\/training.cochrane.org\/handbook\/current."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/89.9.873"},{"key":"e_1_2_8_33_1","unstructured":"European patients' academy glossary [cited 2019 April 29]. Available from:https:\/\/www.eupati.eu\/glossary\/."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007101156"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02840608"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087212"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.08.001"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.80"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23582"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.15587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15587","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:38:38Z","timestamp":1694183918000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/trf.15587"],"URL":"https:\/\/doi.org\/10.1111\/trf.15587","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"2019-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}